WT1 and neoplasm: WT1 is an excellent tumor-associated antigen to target for immunotherapy and WT1 vaccine-based clinical trials have proved safety and efficacy (Sakai et al. 2017; Tsuboi et al. 2019; Sampson et al. 2020).